AI assistant
BeOne Medicines Ltd. — Director's Dealing 2019
Sep 6, 2019
30073_dirs_2019-09-05_10fd9c52-8a23-421d-9bf4-42280efd7d75.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2019-09-03
Reporting Person: Huang Jane (CMO, Hematology)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-09-03 | American Depositary Shares | S | 2632 | $144.4083 | Disposed | 230 | Direct |
| 2019-09-03 | American Depositary Shares | S | 230 | $144.9439 | Disposed | 0 | Direct |
| 2019-09-04 | American Depositary Shares | S | 82 | $129.3971 | Disposed | 0 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 291667 | Direct |
Footnotes
F1: Each American Depositary Share ("ADS") represents 13 Ordinary Shares.
F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax obligation in connection with the vesting of a restricted share award previously granted to the Reporting Person.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.88 to $144.84, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of ADSs, sold at each separate price.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.90 to $144.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of ADSs, sold at each separate price.
F5: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F6: These shares were acquired under the BeiGene, Ltd. Second Amended and Restated Employee Share Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).